Back

Eligibility for semaglutide according to the SELECT trial in a Portuguese cohort of acute coronary syndrome

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention Obesity HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Vanessa Lopes

Centro Hospitalar E Universitario De Coimbra, Coimbra (Portugal)

5 More presentations in this session

Presentation thumbnail
Evaluation of the triglyceride-glucose index as a predictor of metabolic syndrome in elderly population. EVITGA-60 study
Doctor L. Calvo Betancourt (Bogota, CO)
Abstract Slides Video
Presentation thumbnail
Cardiovascular diseases and type 2 diabetes mellitus: high heart failure risk and low rate contraindications to SGLT2i
Doctor V. Medovchshikov (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Prevalence and incidence of heart failure in patients with type 2 diabetes mellitus. Results of the prospective DIABET-IC study
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
CTO recanalization in type 2 diabetic patients: procedural and long-term prognosis
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on exercise-induced hypertrophy: insights from a rodent model of athlete's heart
Doctor A. Olah (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the swedish AROS study
thumbnail
Congress Presentation
Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial
thumbnail
Congress Presentation
Generalizability of SELECT to a contemporary cohort of cardiac surgical patients: analysis of the TRICS III Randomized Trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources